Anzeige
Mehr »
Login
Freitag, 08.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
4.000 Meilen, um herauszufinden, warum der „Warren Buffett des Bergbaus" in diese Kupferaktie investierte
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
499 Leser
Artikel bewerten:
(2)

KBC Groep: KBC Bank Ireland sells substantially all of its remaining non-performing mortgage loan portfolio

Press Release

Outside trading hours - Regulated information*

Brussels, Dublin, 30 August 2021 (8.00 a.m. CEST, before stock exchange hours)

KBC Bank Ireland sells substantially all of its remaining non-performing mortgage loan portfolio

No immediate changes or actions for customers.

Following the announcement made on the 16th April 2021 by KBC Group and KBC Bank Ireland that they were exploring options to divest the remaining non-performing mortgage loan portfolio of KBC Bank Ireland, KBC Bank Ireland can now confirm it has reached agreement to dispose of a non-performing mortgage loan portfolio of roughly 1.1 billion euros (Private Dwelling House (PDH) and Buy to let (BTL) and a small number of non-mortgage non-performing loans) in a transaction financed by funds managed by CarVal Investors ("CarVal").

Post completion, Pepper Finance Corporation (Ireland) DAC will be managing the loans as Legal Title Holder. Pepper is regulated by the Central Bank of Ireland. Customers will continue to have the same legal and regulatory protections (for example under the Consumer Protection Code (CPC) and the Code of Conduct on Mortgage Arrears (CCMA)) after the sale.

There is no immediate change for customers. KBC Bank Ireland customers do not need to take any action as a result of today's announcement. Prior to the closing of the transaction, KBC Bank Ireland will contact the customers whose loan(s) is/are included in the sale, to inform them that their loan(s) is/are being transferred.

The transaction is marginally capital accretive with a combined impact (P&L and RWA) on the pro-forma 2Q21 CET1 ratio of KBC Group of approximately 2bps. It will have an impact on KBC Group's P&L, almost fully booked in 3Q21, which is estimated at -0.1 billion euros. The risk-weighted assets decrease by 0.8 billion euros.

Johan Thijs, KBC Group CEO welcomed today's transaction: "In the past few years, KBC Bank Ireland already gradually built down its legacy non-performing corporate loan portfolio and buy to let mortgage loan portfolio in Ireland. These sales have now been complemented with the sale of substantially all of the remaining non-performing mortgage loan portfolio. This transaction allows KBC Bank Ireland to clean up legacy and further reduce its NPL ratio."

KBC Bank Ireland CEO, Ales Blazek commented: "I'm confident that the agreement we have signed for the sale of substantially all of the remaining non-performing mortgage loan portfolio, and with Pepper managing the loans post completion, offers a good and sustainable solution for our non-performing mortgage loan customers. We can assure that any customers whose loans are included in the transaction will continue to be afforded the same legal and regulatory protections. Pepper is a well established player in the Irish market. Affected customers will be contacted shortly regarding concrete steps related to them."

Note to the editors

CarVal Investors is an established global alternative investment manager focused on distressed and credit-intensive assets and market inefficiencies. Since 1987, CarVal's team has navigated through ever-changing credit market cycles, opportunistically investing $130 billion in 5,550 transactions across 82 countries. Today, CarVal Investors has approximately $10 billion in assets under management in corporate securities, loan portfolios, structured credit and hard assets.

Pepper Finance Corporation (Ireland) DAC ("Pepper") will be managing the loans post completion as the Legal Title Holder and the lender of record. Pepper is regulated by the Central Bank of Ireland, so all customers will continue to be afforded all regulatory protections.

For more information, please contact:

KBC Group :

Viviane Huybrecht, General Manager, Corporate Communication/Spokesperson, KBC Group

Tel +32 2 429 85 45 - E-mail: viviane.huybrecht@kbc.be, pressofficekbc@kbc.be

Website: www.kbc.com

Kurt De Baenst, General Manager, Investor Relations, KBC Group

Tel +32 2 429 35 73 - E-mail: IR4U@kbc.be

KBC Bank Ireland

Edelman - Joe Carmody, CEO - Tel + 353 86 805 87 64 joe.carmody@edelman.com

* This news item contains information that is subject to the transparency regulations for listed companies.


KBC Group NV

Havenlaan 2 - 1080 Brussels

Viviane Huybrecht

General Manager

CorporateCommunication /Spokesperson

Tel. +32 2 429 85 45



Press Office

Tel. +32 2 429 65 01 Stef Leunens

Tel. +32 2 429 29 15 Ilse De Muyer

Tel. +32 2 429 32 88 Pieter Kussé

Tel. +32 2 429 85 44 Sofie Spiessens

E-mail: pressofficekbc@kbc.be (mailto:pressofficekbc@kbc.be)



KBC press releases are available at www.kbc.com (http://www.kbc.com/) or can be obtained by sending an e-mail to pressofficekbc@kbc.be (mailto:pressofficekbc@kbc.be)

Follow us on www.twitter.com/kbc_group (http://www.twitter.com/kbc_group)
Stay up-to-date on all innovative solutions (https://www.kbc.com/en/newsroom/innovation/innovatie-2021.html?zone=topnav)

Attachment

  • 20210830-pb-kbcie-npl-portfolio-en (https://ml-eu.globenewswire.com/Resource/Download/e6fdf684-f448-4b4e-9056-fe4f61bf743f)

© 2021 GlobeNewswire (Europe)
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.